With the first official biosimilar closer to reaching the U.S. market, strategies for marketing the lower-cost biologics are evolving. Debate at the Pharmaceutical Strategy Conference showcased differing views about how best to position biosimilars to patients, physicians and payers.
Amgen Inc. hopes to leverage its expertise in biologics manufacturing to stand out in the market, and believes nuances...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?